Systematic review and meta-analysis shows olanzapine reduces chemotherapy-induced nausea in patients, suggesting potential for lower doses.
Key Points
Olanzapine demonstrated an overall complete response rate of 72% for chemotherapy-induced nausea and vomiting.
The analysis included 24 studies, revealing comparable efficacy between 5 mg/day and 10 mg/day olanzapine in patients receiving highly emetogenic chemotherapy.
Subgroup analysis indicated a significant improvement with 5 mg/day in moderately emetogenic chemotherapy, highlighting its effectiveness.
Low-dose olanzapine at 2.5 mg/day showed potential as an effective option for managing chemotherapy-induced nausea and vomiting.